Join Growin Stock Community!

Indaptus therapeutics, inc.INDP.US Overview

US StockHealthcare
(No presentation for INDP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

INDP AI Insights

INDP Overall Performance

INDP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

INDP Recent Performance

-8.25%

Indaptus therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

INDP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

INDP Key Information

INDP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

INDP Profile

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Price of INDP

INDP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

INDP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-9.63
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.00
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-9.63
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.00
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is INDP's latest earnings report released?

    The most recent financial report for Indaptus therapeutics, inc. (INDP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating INDP's short-term business performance and financial health. For the latest updates on INDP's earnings releases, visit this page regularly.

  • How much cash does INDP have?

    At the end of the period, Indaptus therapeutics, inc. (INDP) held Total Cash and Cash Equivalents of 5.83M, accounting for 0.85 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is INDP's EPS continuing to grow?

    According to the past four quarterly reports, Indaptus therapeutics, inc. (INDP)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -2.98. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of INDP?

    Indaptus therapeutics, inc. (INDP)'s Free Cash Flow (FCF) for the period is -2.57M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 2.16% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.